Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing

Cytogenetic aberrations identified by metaphase cytogenetics (MC) have diagnostic, prognostic, and therapeutic implications in myelodysplastic syndromes (MDS). However, in some MDS patients MC study is unsuccesful. Single nucleotide polymorphism array (SNP‐A) based karyotyping could be helpful in these cases. We performed SNP‐A in 62 samples from bone marrow or peripheral blood of primary MDS with an unsuccessful MC study. SNP‐A analysis enabled the detection of aberrations in 31 (50%) patients. We used the copy number alteration information to apply the International Prognostic Scoring System (IPSS) and we observed differences in survival between the low/intermediate‐1 and intermediate‐2/high risk patients. We also saw differences in survival between very low/low/intermediate and the high/very high patients when we applied the revised IPSS (IPSS‐R). In conclusion, SNP‐A can be used successfully in PB samples and the identification of CNA by SNP‐A improve the diagnostic and prognostic evaluation of this group of MDS patients. © 2013 Wiley Periodicals, Inc.

[1]  E. Campo,et al.  Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: Review of 5,654 patients with an evaluable karyotype , 2013, Genes, chromosomes & cancer.

[2]  G. Mufti,et al.  Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome. , 2012, Blood.

[3]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[4]  F. Solé,et al.  Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia? , 2012, Leukemia research.

[5]  Z. Zemanová,et al.  From cryptic chromosomal lesions to pathologically relevant genes: Integration of SNP‐array with gene expression profiling in myelodysplastic syndrome with normal karyotype , 2012, Genes, chromosomes & cancer.

[6]  Hui Jiang,et al.  The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure. , 2012, Leukemia research.

[7]  Peter J Campbell,et al.  Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.

[8]  M. Cazzola,et al.  Identification of genomic aberrations associated with disease transformation by means of high‐resolution SNP array analysis in patients with myeloproliferative neoplasm , 2011, American journal of hematology.

[9]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[10]  M. McDevitt,et al.  Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. , 2011, Blood.

[11]  F. Solé,et al.  Will a Peripheral Blood (PB) Sample Yield the Same Diagnostic and Prognostic Cytogenetic Data as the Concomitant Bone Marrow (BM) In Myelodysplasia? An International Study Comparing Cytogenetics and Interphase FISH Using Parallel PB and BM Samples , 2010 .

[12]  L. Trümper,et al.  FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients. , 2010, Leukemia research.

[13]  R. Kuiper,et al.  Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.

[14]  Stefan Heinrichs,et al.  SNP array analysis in hematologic malignancies: avoiding false discoveries. , 2010, Blood.

[15]  Michael A McDevitt,et al.  Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. , 2010, Blood.

[16]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[17]  C. O'keefe,et al.  Application of array‐based whole genome scanning technologies as a cytogenetic tool in haematological malignancies , 2009, British journal of haematology.

[18]  M. McDevitt,et al.  TP53 Mutations in Myeloid Malignancies are either Homozygous or Hemizygous due to Copy Number-Neutral Loss of Heterozygosity or Deletion of 17p , 2009, Leukemia.

[19]  A. Hagemeijer,et al.  Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.

[20]  C. Steidl,et al.  P030 Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS) , 2009 .

[21]  M. Loh,et al.  Accurate Detection of Uniparental Disomy and Microdeletions by SNP Array Analysis in Myelodysplastic Syndromes with Normal Cytogenetics , 2009, Leukemia.

[22]  L. Arenillas,et al.  Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q- , 2008, Haematologica.

[23]  C. O'keefe,et al.  Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. , 2008, Blood.

[24]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[25]  G. Mufti,et al.  Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. , 2007, Blood.

[26]  C. O'keefe,et al.  Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. , 2007, Experimental hematology.

[27]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[28]  D. Neuberg,et al.  Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. , 2003, Leukemia research.

[29]  R. Kralovics,et al.  Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. , 2002, Experimental hematology.

[30]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[31]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[32]  G. Garcia-Manero,et al.  SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. , 2012, Blood.

[33]  J. Cigudosa,et al.  Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. , 2005, Haematologica.